[Ticker Inside] Momentum play with extreme potential to skyrocket

[Ticker Inside] Momentum play with extreme potential to skyrocket Here’s our promising alert, PTEO! Turn your attention to this play immediately as we guarantee you there will be high impact action on it. PTEO’s current technical setup indicates us that there is huge potential for serious upticks. By looking at its current chart you’ll see that its no stranger to high upspikes. And according to our indications, today could be another one of those days! This stock’s 52-week high is .194 and at its current price is .03 that’s more than 500% upside from this level, and we could see that climb towards that high starting today. We think that this stock’s quote could possibly reach the potential of that high. If not immediately now today, then for sure in the near future. PTEO or Proteo,Inc is a clinical stage drug development company and intends to develop, promote and market pharmaceuticals and other biotech products. The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. ([www.proteo.us](). The company has one wholly owned subsidiary, Proteo Biotech AG, Kiel, Germany ([www.proteo.de](). Biopharmaceutical companies have raised unprecedented amounts of capital over the past four years (combined public and private market funding in excess of $100B annually), most of it to fund clinical drug development. The biotech company stock market index is the third best performing sector over the last 10 years, supported by premium M&A exits. Capital continues to flow into the sector, stocking the coffers to fund drug development and providing continued momentum for outsourced pharmaceutical services providers. The rate of outsourcing continues to increase, producing outsourced pharma services market CAGR of 7.8%, which is more than 2.5x the already healthy average annual 3.1% increase in pharma industry R&D spending. Currently PTEO is focusing on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Elafin for life threatening surgeries and life-threatening diseases such as PAH. Proteo seeks partners and investors for the development, commercial scale manufacturing, marketing and distribution of the product. Recently PTEO announced the start of the clinical development for the subcutaneous use of Proteo’s lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. Proteo’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene Rabinovitch and Dr. Roham Zamanian, are responsible for the conduct of the investigator-initiated trial. The trial with the title “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” marks the beginning of the clinical development program of Elafin for chronic use initially focusing on the treatment of patients suffering from the still fatal disease pulmonary arterial hypertension (PAH). Elafin has received orphan drug designations in the USA and the EU for the treatment of PAH. Earlier this year PTEO announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that the Proteo R&D test site is able to conduct the archiving of documents related to in-house development products in compliance with the Principles of GLP. The establishment of a GLP quality management system is supported by a BFEI grant from the German State of Schleswig-Holstein. MARKET OUTLOOK The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs. The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market. There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies. In recent years, there has been a rising demand for specialty medicines that is expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the specialty medicines are small molecules. The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress. Get PTEO on your screens now and see the potential for yourself. Sources: [( []( [( Monster Media, LLC 9 Downing St Newark, NJ 07105 UNITED STATES [Unsubscribe](